Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05922709
Other study ID # CS12192-101
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date July 20, 2023
Est. completion date February 1, 2024

Study information

Verified date October 2023
Source Chipscreen Biosciences, Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study is to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profiles of CS12192 after single or multiple oral administration, as well as the food effect on the pharmacokinetics in healthy subjects.


Description:

This study consists of 3 parts: single ascending dose (SAD), multiple ascending dose (MAD) and food effect (FE). Both SAD and MAD study are randomized, double-blind, placebo-controlled design. The FE study use a randomized, open-label, two-period, two-crossover design.


Recruitment information / eligibility

Status Completed
Enrollment 108
Est. completion date February 1, 2024
Est. primary completion date February 1, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - Healthy subjects, both male and female. - Between18 and 45 years of age (inclusive) at screening visit. - BMI between 19.0-26.0 kg/m2 (including critical value) at screening visit and baseline visit, male subjects' body weight = 50 kg, female subjects' body weight =45 kg. - All subjects and female partners of male agree to use medically recognized effective contraceptive measures (including physical contraception, surgical contraception, abstinence, etc.) from the start of signing informed consent form to 3 months after the last dose. - Subjects voluntarily participate in the study and sign informed consent form. Exclusion Criteria: - History of clinically significant drug allergy or atopic allergic diseases (asthma, urticaria, eczematous dermatitis) or drug allergy to investigational products or similar investigational products. - History of cardiovascular system, endocrine system, nervous system disease or lung, hematological, immunological, psychiatric diseases and metabolic abnormalities. - History or surgical history of gastrointestinal, hepatic, or renal disease that can affect drug absorption or metabolism within 6 months prior to the screening visit (except uncomplicated appendectomy and hernia repair). - History of active tuberculosis, or positive tuberculosis screening at screening visit. - History of any recurrent bacterial, fungal or viral infections (=3 attacks in the past year, except the common cold), or active infections requiring treatment at screening visit, or history of infection requiring intravenous anti-infective drugs or hospitalization =8 weeks before randomization, or history of infection requiring oral anti-infective drugs =2 weeks before randomization. - Uncured diarrhea before randomization, or history of diarrhea within 7 days before planning dosing. - Use of any prescription drugs, over-the-counter drugs, any vitamin products or Chinese herbal medicines within 1 month before randomization. - History of drug abuse. - Inability to tolerate venipuncture, or history of fainting or halo. - Participation in interventional clinical study (device or drug) within 3 months prior to randomization, or taking investigational product within 3 months prior to randomization , or remaining within 5 half-lives of drug, whichever is longer. - Blood donation or significant blood loss (>300 mL) within 3 months prior to randomization. - Pregnant or lactating females, or female subjects with serum pregnancy test human chorionic gonadotropin (HCG) =5 mIU/mL. - History of regular alcohol consumption, drinking more than 7 cups per week for females or 14 cups per week for males (1 cup= 100 mL wine = 285 mL beer = 25 mL spirits) within 3 months before randomization; or taking any products containing alcohol within 48 hours before the first dose; or having a positive alcohol breath test before randomization. - Smoking more than 5 cigarettes or equivalent per day within 3 months prior to randomization or inability to refrain from smoking during the trail. - Excessive consumption of tea, coffee or caffeinated beverages (more than 8 cups) per day within 14 days before randomization, or tea, coffee, caffeinated beverages or foods within 48 hours before randomization. - Consumption of grapefruit or beverages or foods containing its ingredients within 14 days before randomization. - Glomerular filtration rate (eGFR) <80 mL/min at screening visit and baseline visit (calculating by using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation for serum creatinine, age, and sex). - Abnormal results in medical history inquiry, vital signs, physical examination, chest X-ray, and clinical laboratory tests are clinically significant. - QTcF=450 ms or other clinically significant abnormality as judging by the investigator on 12-lead ECG at screening visit and baseline visit. - Human immunodeficiency virus antibody (HIV) cannot provide negative reports at screening visit. - Syphilis serology, hepatitis B virus surface antigen (HBsAg), hepatitis B virus-DNA quantification, or hepatitis C virus antibody (HCV-Ab) positive at screening visit. - Positive urine drug screening (morphine, methamphetamine, ketamine, ecstasy, marijuana, cocaine) before randomization. - Need or plan to engage in strenuous physical activity or exercise during the study. - Inability to tolerate high-fat and high-fever meal (only for fed study). - Subjects with dysphagia. - Other conditions considered inappropriate for participation in the study by the investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
CS12192 capsule
Participants receive CS12192 orally single or multiple doses
Placebo capsule
Participants receive placebo matching CS12192 orally single or multiple doses

Locations

Country Name City State
China Zhongshan Hospital Affiliated to Fudan University Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Chipscreen Biosciences, Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary the Number of Adverse Events (AEs) To investigate the safety and tolerability by assesment of AEs following administration. up to 14 days
Primary Pharmacokinetic parameters - Area Under the Curve(AUC) Area Under the Plasma Concentration-time Curve of CS12192. From time 0 to 48 hours for single dose. From time 0 to 48 hours after the last dose for multiple doses. From time 0 to 48 hours after the last dose for food effect study.
Primary Pharmacokinetic parameters - Peak Plasma Concentration (Cmax) Maximum Observed Plasma Concentration of CS12192. From time 0 to 48 hours for single dose. From time 0 to 48 hours after the last dose for multiple doses. From time 0 to 48 hours after the last dose for food effect study.
Primary Pharmacokinetic parameters - Time of peak concentration(Tmax) Time to reach maximum observed plasma concentration of CS12192. From time 0 to 48 hours for single dose. From time 0 to 48 hours after the last dose for multiple doses.From time 0 to 48 hours after the last dose for food effect study. From time 0 to 48 hours after the last dose for food effect study.
Primary Pharmacokinetic parameters - Plasma Elimination Half-Life(t1/2) Plasma Elimination Half-Life of CS12192. From time 0 to 48 hours for single dose. From time 0 to 48 hours after the last dose for multiple doses.From time 0 to 48 hours after the last dose for food effect study. From time 0 to 48 hours after the last dose for food effect study.
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1